type 2 diabetes
Conditions
Interventions
3 months-observation by alogliptin treatment
3 months-observation by combination treatment with alogliptin and lansoprazole
Sponsors
Dokkyo Medical University Koshigaya Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) patients aged 20 or over 2) patients diagnosed as type 2 diabetes 3)outpatient 4)patients with 6.5% and over of HbA1c levels, and plus, with 0.5% or less variation of HbA1c in 1 month before starting administration of drugs 5)patients who did not receive DPP4 inhibitors during 1 month before starting study 6) patients in whom type and dose of all anti-diabetic drugs was not changed during 1 month before starting study 7)patients giving consent in writing for participation for this study
Exclusion criteria
Exclusion criteria: 1)Patients with severe ketosis, diabetic coma or diabetic pre-coma, or type 1 diabetes 2)Patients with severe infectious diseases, within 1 month after operation, or having severe traumatic injury 3)Patients with allergy for component of alogliptin or lansoprazole 4)Patients under atazanavir-treatment 5)Patients treated with PPIs of all types or H2-blockers of all types 6)Furthermore, patients judged as inadequacy for participation in this study by medical doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HbA1c and fasting plasma glucose (FPG) levels 3 months after starting the study | — |
Secondary
| Measure | Time frame |
|---|---|
| Fasting gastrin and insulin levels, HOMA-R, HOMA-beta, Body weight 3 months after starting the study | — |
Countries
Japan
Contacts
Public ContactKohzo Takebayashi
Dokkyo Medical University Koshigaya Hospital Internal Medicine (Diabetes, Endocrinology,Hematology)
Outcome results
None listed